Previous 10 | Next 10 |
Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company’s proprietary biologic product candidates to cross intestinal epithelial barrier Deep characterization of natural molecular ...
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical ex...
Gainers: Qurate Retail (QRTEA) +19%. lululemon athletica (LULU) +7%. Cue Health (HLTH) +7%. Spero Therapeutics (SPRO) +6%. Applied Molecular Transport (AMTI) +6%. Losers: Stronghold Digital Mining (SDIG) -26%. Braze (BRZE) -11%. Global-E Online ...
Company continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: A...
As the Russian invasion of Ukraine continues, several pharma and biotech companies have exposure to both countries through clinical trials being conducted there. One biotech, Karuna Therapeutics (NASDAQ:KRTX), has already said the disturbance has impacted a late-stage trial. On Thursday, the ...
Applied Molecular Transport press release (NASDAQ:AMTI): Q4 GAAP EPS of -$0.78 misses by $0.12. “We are looking forward to a catalyst-rich year in 2022 for AMT,” said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. “The Company is well-prepared a...
Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as follows FILLMORE monotherapy trial for patients with chronic pouchitis followed by MARKET combination trial with anti-TNF α in ulcerative colitis (UC) in H1 2022 LO...
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the...
John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair Graham K. Cooper Named Executive Chair Helen S. Kim Named Lead Independent Director SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Tran...
Gainers: iSpecimen ISPC +117%. Biofrontera BFRI +75%. Allied Healthcare Products AHPI +64%. NRx Pharmaceuticals NRXP +57%. Adagio Therapeutics ADGI +30%. Losers: Procaps Group (NASDAQ:PROC) -18%. Jowell Global Ltd (NASDAQ:JWEL) -17%. Pinduoduo PD...
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Applied Molecular Transport Inc. Website:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...